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Antje Bakker3, Nina Sohnius-Wilhelmi3, Carolina Frankl-Vilches3, Annemie Van der Linden4, 
Wim Van Criekinge1, Wim Vanden Berghe2 & Tim De Meyer1
Learning and memory formation are known to require dynamic CpG (de)methylation and gene 
expression changes. Here, we aimed at establishing a genome-wide DNA methylation map of the 
zebra finch genome, a model organism in neuroscience, as well as identifying putatively epigenetically 
regulated genes. RNA- and MethylCap-seq experiments were performed on two zebra finch cell lines 
in presence or absence of 5-aza-2′-deoxycytidine induced demethylation. First, the MethylCap-seq 
methodology was validated in zebra finch by comparison with RRBS-generated data. To assess the 
influence of (variable) methylation on gene expression, RNA-seq experiments were performed as 
well. Comparison of RNA-seq and MethylCap-seq results showed that at least 357 of the 3,457 AZA-
upregulated genes are putatively regulated by methylation in the promoter region, for which a pathway 
analysis showed remarkable enrichment for neurological networks. A subset of genes was validated 
using Exon Arrays, quantitative RT-PCR and CpG pyrosequencing on bisulfite-treated samples. To our 
knowledge, this study provides the first genome-wide DNA methylation map of the zebra finch genome 
as well as a comprehensive set of genes of which transcription is under putative methylation control.
In the past few decades, songbirds became a widely used model system in the behavioral neurobiology of learn-
ing1, evolutionary genetics2, neuroendocrinology3 – particularly the sexual differentiation of the brain – and adult 
neurogenesis4. Songbirds evolved the ability to learn vocalizations by copying a singing adult. Vocal learning is 
a trait that songbirds share with humans, where it forms the basis of spoken language acquisition, but which 
is absent in traditional model organisms such as rodents and nonhuman primates5. The presence of multiple 
behavioral parallels between song learning and human speech learning makes it plausible that there are similar 
underlying neurobiological pathways involved6,7. Indeed, it has become apparent that there are striking homolo-
gies between the brains of birds and mammals, leading to the identification of common neuronal and molecular 
substrates8.
One songbird in particular, the zebra finch (Taeniopygia guttata), has been the focus of many studies because 
of its rapid maturation and its tendency to sing and breed in captivity5,7, highlighted by the availability of its com-
plete genome sequence9. Although numerous genomic resources are becoming available for this animal model, 
several in vivo experiments (e.g. knockdowns or manipulation of gene expression), are still impossible or very 
laborious and expensive. Fortunately, recently two immortalized zebra finch cell lines were established, i.e. the 
diploid male G266 and tetraploid female ZFTMA cell line, both obtained from spontaneous, non-neuronal tum-
ors, providing an efficient alternative to whole-animal manipulations10. Although these cell lines are not derived 
from brain tissue, it has previously been observed that they express many neurobiologically relevant genes11.
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Epigenetic modifications, including DNA methylation, have been shown to play an important role in several 
neurobiological and cognitive processes, such as learning and memory12,13. Epigenetics is defined as the study 
of inheritable chromatin modifications that have an impact on gene expression without altering the underlying 
DNA sequence14. DNA methylation is a well-known epigenetic mark that is essential for normal development. 
It is established by DNA methyltransferases (DNMTs) and involves the transfer of a methyl group to cytosine 
residues at the carbon 5 position, predominantly in a CpG context. This methylation mark is known to regulate 
gene expression and when located in the promoter region, it generally leads to transcriptional silencing of the 
corresponding gene15. DNA methylation has traditionally been regarded as a highly stable epigenetic mark in 
post-mitotic cells, defining their cellular identity. However, it has been observed that the postnatal brain shows 
stimulus-induced de novo CpG methylation or active DNA demethylation at specific loci during the process 
of learning and memory formation16–18. For example, there is accumulating evidence that the expression of 
brain-derived neurotrophic factor (BDNF) is regulated by epigenetic modifications, and in particularly by pro-
moter DNA methylation19. BDNF is a neurotrophic factor important for neuronal activity-dependent processes 
such as long term-potentiation, neuronal survival, development, memory formation and synaptic plasticity, 
which is linked to several neurological disorders e.g. schizophrenia and mood disorders20,21.
Even though zebra finches are an attractive model to study the molecular basis of (vocal) learning, a 
genome-wide DNA methylation pattern in this species is currently lacking. In order to assess a first ‘draft of 
the zebra finch methylome’, we performed methyl-CpG binding domain protein sequencing (MethylCap-seq) 
experiments on the G266 as well as the ZFTMA cell line, in presence or absence of the DNA methylation inhib-
itor 5-aza-2′ -deoxycytidine (AZA) that, when incorporated in the genome, inhibits DNMTs resulting in a 
net demethylation effect22. MethylCap-seq is based on the specific enrichment of methylated portions of the 
genome (i.e. enrichment-based method) by Methyl-CpG Binding Domain (MBD)-based affinity purification 
followed by massively parallel sequencing23,24. Contrasting whole-genome bisulfite sequencing, it provides a 
cost-efficient option to assess genome-wide DNA methylation profiles25. However, until now MethylCap-seq has 
primarily been used for human and mouse genomes, and its effectiveness has not yet been demonstrated in zebra 
finch. Here, we evaluate the quality and sensitivity of this methodology for zebra finch by comparison with a 
species-independent, though not genome-wide, methodology, i.e. Reduced Representation Bisulfite Sequencing 
(RRBS)26. By comparing MethylCap-seq data of dimethyl sulfoxide (DMSO, solvent control) and AZA-treated 
samples it was possible to identify genomic regions that are substantially demethylated due to the treatment. 
Moreover, to assess the effect of AZA-induced demethylation on gene expression RNA-seq experiments were per-
formed, which were validated by performing zebra finch Exon Array analysis. Subsequently, a pathway analysis 
was accomplished on the resulting set of loci, and a subset was validated by independent methodologies i.e. CpG 
pyrosequencing and quantitative Real-Time PCR (qPCR).
To our knowledge, this study provides the first genome-wide draft methylome of the zebra finch. The inclusion 
of AZA-treated samples allows the identification of loci, which are nearly always methylated, or – more impor-
tantly – for which the methylation status is highly variable in different settings. We provide an overview of loci 
featured by dynamic methylation degrees as well as a list of genes for which expression is putatively regulated by 
DNA methylation in the promoter region.
Materials and Methods
Cell cultures and treatments. Two zebra finch cell lines were used: the diploid male G266 cell line and 
the tetraploid female ZFTMA cell line, both derived from spontaneous tumors10. These cell lines were a kind gift 
of Dr. David Clayton (Queen Mary University of London). Cells were cultured in DMEM high glucose medium 
(Life Technologies 41965039) supplemented with 10% heat inactivated fetal bovine serum (Life Technologies 
102070106), 2% heat inactivated chicken serum (Life Technologies 15140122) and 1% penicillin streptomycin 
(Life Technologies 15070063). Cultures were maintained at 37 °C, 5% CO2 and 95–98% humidity.
Cells were treated for 72 hours with 1 μ M concentration of AZA (= demethylation treatment, Sigma-Aldrich 
A3656), with DMSO as a solvent control, or left untreated. Both AZA and DMSO inductions were repeated every 
24 hours, as AZA is known to be relative unstable in aqueous solution. Genomic DNA (gDNA) was extracted 
from an untreated ZFTMA cell line as well as from AZA- and DMSO-treated G266 and ZFTMA cell lines using 
the DNeasy mini kit (Qiagen 69506) while RNA was extracted from AZA- and DMSO-treated G266 and ZFTMA 
cell lines using Trizol and RNeasy mini kit (Qiagen 74106), both according to the manufacturer’s instructions. 
DNA and RNA concentrations were measured using Nanodrop 1000 (Thermo Fisher Scientific).
Library preparation and sequencing. Reduced Representation Bisulfite Sequencing. Bisulfite treat-
ment, library preparation and sequencing of the untreated ZFTMA DNA sample were performed as a commer-
cial service by BaseClear, using the Zymo Research EpiQuest bisulfite and library preparation procedures. For 
this sample, 500 ng gDNA was checked for integrity and lack of degradation by agarose gel electrophoresis and 
the concentration was measured by a non-UV method. The DNA was subsequently fragmented, size selected 
(150–450 bp) and a bisulfite conversion was performed. Next, Illumina adapters were added and the fragments 
amplified with a PCR amplification. The length distribution of the resulting library was checked on a BioAnalyzer 
(Agilent Technologies G2940CA) and quantified. Quantified and converted DNA libraries were loaded on the 
Illumina HiSeq2000 platform and a paired-end sequencing run was performed as subscribed in the Illumina 
protocol ‘performing a multiplexed paired-end run’ (2 times 50 cycles).
Methyl-CpG binding domain protein sequencing. Methyl-CpG binding domain protein sequencing 
(MethylCap-seq), which combines enrichment of methylated DNA fragments by MBD-based affinity purification 
with massively parallel sequencing23, was used to profile the DNA methylation pattern of the DMSO-, AZA- and 
untreated zebra finch cell lines, i.e. G266 and ZFTMA. The gDNA was sheared using Covaris S2 equipment with 
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following settings: duty cycle 10%, intensity 5, 200 cycles per burst during 190 seconds to obtain fragments with 
an envisaged average length of 200 bp. The power mode was frequency sweeping, temperature 6–8 °C and water 
level of 12. 2 μ g was loaded in 130 μ l TE (1:5) in a microtube with AFA intensifier. After DNA fragmentation, the 
methylated fragments were captured using Diagenode’s MethylCapTM kit (Diagenode AF-100-0048) according 
to the manufacturer’s instructions starting from a DNA concentration between 250 and 500 ng. Captured DNA 
was eluted in a 150 μ l High Elution buffer and purified with MinElute PCR purification columns (Qiagen 28006). 
Purified DNA was used for library preparation, which was performed on the Apollo 324TM (IntegenX) using 
the Multiplexing Sample Preparation Oligonucleotide Kit (Illumina PE-400-1001). Size selection (100–350 bp) 
was done with Agencourt AMPure XP beads (Beckman Coulter Inc. (Analis SA) A63882) in combination with 
polyethylene glycol (PEG). 22 μ l of DNA was subjected to PCR following the Illumina Library Amplification 
Index Protocol (Illumina) with 21 cycles of PCR amplification using Phusion High-Fidelity PCR Master Mix 
(New England BioLabs (NEB) M0532L) with primers of the Multiplexing Sample Preparation Oligonucleotide 
Kit (Illumina). PCR products were purified with the High Pure PCR Cleanup Micro Kit (Roche Applied Science 
04983912001). Next, libraries were assessed using an Agilent DNA 1000 Chip (Agilent Technologies 5067–1504). 
The concentration was determined following Illumina’s qPCR Quantification Protocol Guide (Illumina SY-930-
1010). After pooling the libraries, paired-end sequencing was performed as a commercial service by BaseClear on 
one lane (8 samples/lane) of the Illumina HiSeq2000 following the Illumina protocol ‘performing a multiplexed 
paired-end run’ (2 times 50 cycles).
RNA-sequencing. RNA-seq experiments were performed on DMSO- and AZA-treated G266 and ZFTMA cell 
lines. RNA samples were analyzed with both the Quant-iTTM Ribogreen® RNA Assay Kit (Invitrogen R11491) 
and the Agilent Eukaryote Total RNA 6000 Pico Chip (Agilent 5067–1513) to ensure adequate quality and quan-
tity of total RNA. Prior to the library preparation, an rRNA depletion step was performed on 3 μ g input RNA 
(Ribogreen® measurement) using the Ribo-ZeroTM Magnetic Kit (Human/Mouse/Rat, Epicentre MRZH11124). 
Next, cDNA libraries for the ZFTMA and G266 rRNA depleted samples (6 μ l/sample) were prepared using the 
ScriptSeqTM v2 RNA-seq Library Preparation Kit (Epicentre SSV21124) following the manufacturer’s protocol. 
Library amplification was performed with 15 PCR cycles. Quality control of the libraries was assessed using 
an Agilent High Sensitivity DNA Chip (Agilent Technologies 5067–4526). The concentration was determined 
following Illumina’s qPCR Quantification Protocol Guide (Illumina SY-930-1010). After pooling the librar-
ies, paired-end sequencing was again performed by BaseClear on one lane (4 samples/lane) of the Illumina 
HiSeq2000 again following Illumina’s protocol ‘performing a multiplexed paired-end run’ (2 times 50 cycles).
Sequence read mapping. For each sample, MethylCap-seq paired-end reads were mapped with Bowtie2 
(v2.1.0)27. The mapping parameters were chosen so that only paired-end reads that mapped uniquely and con-
cordantly on the zebra finch reference genome (assembly taeGut3.2.4, Ensembl release 72) within a maximum of 
400 bp of each other were retained. Seed mismatches, length and interval during multiseed alignment were set to 
the default values. For RRBS, paired-end reads were mapped with Bismark (v0.9.0) in Bowtie2-mode28. Again, 
default values were chosen for the multiseed alignment and only concordantly, uniquely mapped reads with a 
maximum insert size of 500 bp were withheld. Paired-end RNA-seq reads were mapped with STAR (v2.3.0)29. 
Here, reads mapping up to 10 places on the zebra finch genome were allowed with a maximum of 6 mismatches 
per fragment, i.e. read pair. For MethylCap-seq, duplicate fragments, i.e. fragments with the exact same location 
of both paired-end reads, were disposed as these are most likely the result of amplification of the same sequence 
reads during library preparation. As for RNA-seq and RRBS duplicate reads are expected – they arise from both 
the enzymatic cutting (RRBS)/limited library complexity (RNA-seq) as well as from the PCR step and there is no 
simple way to distinguish between these two sources of duplicate reads – they were retained for further analysis.
Quality control of MethylCap-seq. As our study is the first to use MethylCap-seq – which employs a 
human-derived MBD – on zebra finch samples, it was necessary to first assess the accuracy of this methodol-
ogy in this non-mammal species. MethylCap-seq specifically enriches for methylated genomic regions. Hence, a 
higher amount of MethylCap-seq fragments covering a particular region reflects in general a higher methylation 
degree. Though limited regarding genome-wide information, RRBS is based on bisulfite treatment – and therefore 
species-independent – and can yield a quantitative estimate of the percentage of methylation. As bisulfite treat-
ment only converts non-methylated cytosine residues to uracil, which will be read as a thymine when sequenced, 
whereas methylated cytosine residues remain identified as cytosine, it is possible to summarize the methylation 
state of each sequenced cytosine and CG dinucleotide (= CpG methylation degree). In order to evaluate the effi-
cacy of the performed MethylCap-seq in zebra finch, the MethylCap-seq data of the untreated ZFTMA cell line 
was compared to its corresponding RRBS data. For each RRBS-covered CpG (at least 10 RRBS reads), the CpG 
methylation degree was determined as well as its coverage obtained by MethylCap-seq. Finally, to indicate the 
sensitivity of MethylCap-seq it was examined if higher RRBS CpG methylation degrees are indeed associated with 
more MethylCap-seq fragments.
Read summarization. Prior to the differential expression/methylation analysis, the sequencing reads 
needed to be assigned to genomic features of interest. The mapped RNA-seq reads were converted to fragment 
counts per exon and grouped per gene with the R-package Rsubread (v1.12.0)30. Gene annotations were obtained 
from Ensembl (release 72).
In order to summarize the MethylCap-seq reads, it was necessary to first identify all possibly methylated 
regions in the zebra finch genome (Methylation Peaks), which could subsequently be used as units for statis-
tical analysis, cf. the use of genes in RNA-seq data analysis. As MethylCap-seq data consists of a mixture of 
DNA methylation signal and (relatively low amounts of) noise, only loci that exhibit a sufficiently high signal 
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intensity (i.e. pass a certain threshold) qualify as “potentially methylated”. This classification was done by taking 
the summed coverage of both ZFTMA and G266 cell line control sample results (i.e. DMSO-treated), and by 
evaluating different coverage thresholds – ranging from 1 to 20 – for “significant” methylation. Instead of impos-
ing an arbitrary signal intensity threshold, an optimal threshold was identified by using the RRBS data as “gold 
standard”. Consequently, for threshold identification, only those loci for which RRBS data were available were 
considered, but we made the reasonable assumption that the identified threshold can be applied on the complete 
MethylCap-seq dataset.
In a first step, the MethylCap-seq data for both the ZFTMA and G266 DMSO-treated samples was piled-up for 
an unbiased selection, hereby making the common assumption that the large majority of methylation events are 
conserved between both cell lines. Second, for each CpG measured by RRBS and MethylCap-seq coverage thresh-
old under study, it was assessed whether this CpG was categorized as “methylated” (= MethylCap-seq inten-
sity above threshold), or “unmethylated” (= vice versa). Third, the optimal coverage threshold was determined 
by comparing the RRBS methylation degrees between both categories using the Kruskal-Wallis rank sum test. 
Subsequently, the Methylcap-seq threshold for which this comparison yielded the clearest difference (i.e. lowest 
p-value) was selected as optimal threshold. In other words, for this threshold MethylCap-seq results correspond 
best with the RRBS results.
In a next step, the Methylation Peaks were defined as all genomic regions where every position has a total 
coverage larger than or equal to this optimal coverage threshold. Additionally, these regions were trimmed at 
both ends so that the final regions start and end with a CpG. Finally, for each sample, the non-duplicate, uniquely 
mapped MethylCap-seq reads could be summarized into fragment counts per Methylation Peak.
The corresponding functional genomic annotation (i.e. promoter, exon, intron and intergenic) of the identi-
fied Methylation Peaks was determined using Ensembl (release 72), wherein the promoter was defined as starting 
from 2000 bp upstream until 500 bp downstream of the transcriptional start site. Only if a Methylation Peak had 
none of the genic categories (i.e. promoter, exon, and intron) it was defined as intergenic.
Both circular plots (Circos tool31) and an in-house developed genome browser (H2G2, http://h2g2.ugent.be/
biobix.html) were used for visualization of the experimental data.
Differential methylation and expression analysis. To test whether the methylation pattern in inter-
genic regions was different between gene-deserts, i.e. gene-poor/intergenic regions > 500 kb, and no-gene-deserts, 
i.e. intergenic regions < = 500 kb, the amount of reads in the Methylation Peaks falling in each group was deter-
mined. Per chromosome, the read count of each group was normalized for its respective length, after which a 
t-test was performed comparing the methylation level of both gene-deserts and no-gene-deserts.
Subsequently, we used the R-package EdgeR (v3.4.2)32 to test for both differential methylation degrees 
as well as differential gene expression between the DMSO- and AZA-treated samples. Normalization of 
the MethylCap-seq counts between the two treatments was performed based on the reads that mapped in 
non-Methylation Peaks, i.e. the library size of the “noise reads”. The rationale of this in-house method was that 
despite the performed treatment, the observed noise, i.e. amount of reads between Methylation Peaks, should 
be similar between the two G266 samples as well as between the two ZFTMA samples. Since the putative noise 
regions might still contain some signal as well, this can be considered a conservative approach. Normalization 
of the RNA-seq gene counts was performed with the PoissonSeq package implemented in R (v1.1.2)33. This nor-
malization method is based on a Chi-square-like goodness-of-fit statistic and has been shown to perform better 
than other existing methods (e.g. trimmed mean of M-values (TMM)34, DESeq35, quantile and library size nor-
malization). Because the global differences between the DMSO- (= control) and AZA-treated (= demethylation 
treatment) samples are of primary interest, and not the differences between the two cell lines nor the treatment 
effect that occurs for only one cell line, a paired design was chosen – which also accounts for the different ploidy 
levels between the two cell lines. Resulting p-values were adjusted using the Benjamini-Hochberg correction and 
only Methylation Peaks (or genes) that were significant at a false discovery rate (FDR) of 0.1 were considered as 
differentially methylated (or expressed).
Enrichment analysis. Next, we tested the list of differentially methylated genomic regions between DMSO- 
and AZA-treated samples for enrichment in one or more functional categories (i.e. promoter, exon, intron and 
intergenic). By random sampling from the total amount of Methylation Peaks and counting the occurrences of 
the respective annotations, a null distribution was generated. During this sampling procedure, the number of 
Methylation Peaks sampled for each chromosome was equal to the number of significantly down-methylated 
Methylation Peaks for that chromosome. Sampling was repeated 1,000 times. Based on the null distribution 
obtained for promoter, exonic, intronic and intergenic regions it was possible to calculate a two-sided p-value for 
each of these categories.
For Methylation Peaks that were featured by more than one genic annotation (i.e. overlapping genes and/
or different transcripts and/or sense and antisense strand and/or peaks overlapping different locations on same 
strand) the attributed score of the functional location was divided by the amount of different categories for this 
peak (the sum always being one). For example, if a Methylation Peak is located in an exon on the sense strand but 
is also located in an intron on the other strand, both “exon” and “intron” categories were attributed a score of 0.5.
As the AZA-treatment normally leads to demethylation and we were particularly interested in demethylation 
that results in upregulated expression, a similar analysis was performed only one those genomic regions which 
were significantly down-methylated and located in genes significantly upregulated by AZA-treatment. The func-
tional genic annotation (i.e. promoter, exon and intron) of these Methylation Peaks was determined as described 
above. Likewise, two-sided p-values were calculated for each genic annotation, after random sampling from the 
whole set of Methylation Peaks located in upregulated genes.
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Ingenuity Pathway Analysis. To interpret the results in the context of biological processes, regulatory 
networks and other pathways, Ingenuity Pathway Analysis (IPA) (Ingenuity Systems®, www.ingenuity.com) 
was performed. The IPA software provides a comprehensive database of known networks and pathways that 
are constantly being updated based on published literature on gene functions and interactions. After providing 
the Ensembl gene identifiers of the target genes to IPA (fall release 2015) the most affected/involved biological 
processes and networks are listed and scored based on significance. In addition, also possible relationships with 
diseases and disorders are shown. The provided gene list consisted of genes that upon AZA-treatment were signif-
icantly upregulated and featured by at least one Methylation Peak exhibiting significant AZA-induced demethyla-
tion in the promoter region (i.e. genes that are under putative DNA methylation control). P-values were corrected 
for multiple testing using the Benjamini-Hochberg method.
Validation: Zebra finch Exon Arrays and Quantitative Real Time-PCR. To confirm the RNA-seq 
findings, we performed zebra finch Exon Arrays (Affymetrix custom designed) on independent samples. Total 
RNA was extracted using Trizol and the RNeasy Mini Kit (#74104, Qiagen Inc., Valencia, CA, USA) accord-
ing to the manufacturer’s protocol including the optional DNA digestion step. RNA quality was assessed using 
an Agilent Model 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) and the RNA concentration 
was determined with a Nanodrop 1000 spectrometer (Thermo Fisher Scientific, Wilmington, MA, USA). For 
each sample, 100 ng of total RNA was processed for hybridization on the microarray using the Ambion® WT 
Expression Kit and (#4411974, Thermo Fisher Scientific Inc.), the GeneChip® WT Terminal Labeling and 
Controls Kit (#901524, Affymetrix® Microarray Solutions) and the GeneChip® Hybridization, Wash, and Stain 
Kit (#900720, Affymetrix® Microarray Solutions). The resulting cDNA was hybridized to the custom designed 
Affymetrix Gene Chip® MPIO-ZF1s520811 Exon Array as described by Frankl-Vilches et al. 201536 and scanned 
with the GeneChip® Scanner 3000 7G (#00–0210, Affymetrix® Microarray Solutions). CEL files generated by the 
Affymetrix® GeneChip® Command Console® Software (AGCC) were imported into ChipInspector software, 
version 21 (El Dorado Database version: E30R1410 Genomatix GmbH). Differential expression between DMSO 
and AZA (500 nM) treated samples was analyzed using the group-wise exhaustive analysis with false discov-
ery rate set to zero and 10-significant probe minimum coverage. CEL files, raw data and additional statistical 
information have been deposited in NCBI’s Gene Expression Omnibus65 and are accessible through GEO Series 
accession number GSE71344).
In order to determine whether the expression level correlates to the methylation status, 7 genes were selected 
that showed a significant increase in gene expression (both RNA-seq and Exon Arrays) and decrease in pro-
moter DNA methylation (MethylCap-seq): BDNF37, neuroglobin (NGB)38, HES family BHLH transcription 
factor 1–4 (HES1-4)39, GABA(A) receptor subunit delta (GABRD)40, ankyrin 1 (ANK1)41, matrix metallopep-
tidase 9 (MMP9)42 and inhibitor of kappa light polypeptide gene enhancer in B-cells kinase epsilon (IKBKE). 
Three independent biological replicates of DMSO- and AZA-treated samples were used for the validation exper-
iments. Gene-specific qPCR primers were designed using PrimerBlast (NCBI) (Table 1). Total RNA was isolated 
as described above. 1 μ g of RNA was subsequently converted into cDNA using oligodT primers and M-MLV 
Reverse transcriptase (Promega). SYBR Green qPCR was performed in triplicate on the Rotor-GeneQ instrument 
(Qiagen) using the Rotor-Gene SYBR Green Fast PCR kit, as follows: 95 °C for 5 min, followed by 45 cycles of 
95 °C for 5 s and 60 °C for 10 s. Dissociation curves were checked to ensure amplification of a single PCR product. 
Moreover, standard curves were run to check the amplification efficiency of each assay. All amplification efficien-
cies were between 100% and 111%, with no major differences between test genes and housekeeping genes.
For each independent biological sample, all cycle threshold (Ct) values for the target genes were normalized 
to the corresponding geometric mean of three housekeeping genes: ribosomal protein L30 (RPL30), ribosomal 
protein S13 (RPS13), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). To compare the expression lev-
els between different treatments, the 2 −ΔΔCt method43 was used and corresponding gene-specific p-values were 
calculated with a two-way ANOVA – using treatment and sample (= 1, 2 or 3) as factors – on the normalized Ct 
values instead of the 2 −ΔΔCt values.
Validation: Single locus specific DNA methylation quantification by CpG pyrosequenc-
ing. Additionally, the MethylCap-seq profiles of BDNF, NGB, HES1-4, GABRD, ANK1, MMP9 and IKBKE 
were validated with CpG pyrosequencing of bisulfite-treated samples (same three independent samples used for 











Table 1.  qPCR primer sequences.
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qPCR validation). PCR amplification and sequencing primers were designed using the Pyromark Assay Design 
v2.0 software (Qiagen). The primers (Table 2) were designed at significant Methylation Peaks in the promoter 
region of the genes of interest. To ensure sufficient bisulfite conversion, a bisulfite conversion control was included 
in each assay.
First, 2 μ g of gDNA was bisulfite converted using the EpiTect Fast Bisulfite Kit (Qiagen). 20 ng of this bisulfite 
converted DNA was then used as a PCR template (reverse primer was biotinylated), using the PyroMark PCR kit 
(Qiagen). Primer annealing temperatures were optimized: 56 °C for BDNF, GABRD, ANK1 and MMP9, 58 °C for 
HES1-4, 59 °C for IKBKE and 60 °C for NGB. Next, 15 μ l of the PCR product was used for CpG pyrosequencing 
on the PyroMark Q24 instrument (Qiagen). Finally, the results were analyzed using the Pyromark Q24 software. 
Methylation values of each cell line were summarized per CpG for both the DMSO- and AZA-treatment and 
gene-specific p-values, i.e. including all CpGs tested for the gene, were obtained using a two-way ANOVA with 
treatment and CpG as factors.
Results
Experimental design. MethylCap-seq and RNA-seq analyses were performed on DMSO- and AZA-treated 
samples (Fig. 1). AZA is a chemical analogue of cytidine, that, when incorporated in the genome, inhibits DNMTs 
resulting in a net demethylation effect22. In addition, an untreated ZFTMA sample was analyzed with MethylCap-
seq and RRBS to validate the MethylCap-seq methodology in zebra finch (quality control).
Sequence read mapping. Table 3 lists the results of the sequence alignment for all libraries. For the 
five MethylCap-seq samples, removal of the duplicate fragments resulted in a lower fraction of non-duplicate, 
uniquely mapped reads for the AZA-treated experiments. Note that mapping of the RRBS paired-end reads 
resulted in a rather low percentage of uniquely mapped reads (28.43%), similar as Chatterjee et al.44 who obtained 
percentages ranging from 27% to 32.7% when uniquely mapping four non-mammal zebrafish RRBS libraries. 
In contrast, RRBS mapping of another non-model species (sheep) resulted in an average unique mapping effi-
ciency of 60%45. These mapping efficiencies depend on both the specific characteristics of the reads and reference 
genome, as well as the used stringency during mapping (see Discussion). After RRBS alignment, the CpG dinu-
cleotides were filtered based on coverage. Only CpG sites covered by 10 or more RRBS reads were retained for 
further analysis. For the RRBS library, this resulted in 1,074,648 CpGs (approximately 11% of total number of 
genomic CpG sites), with a mean coverage of 123 for which subsequently CpG methylation degrees were calcu-
lated (Fig. 2).
MethylCap-seq is an appropriate methodology for studying DNA methylation in zebra 
finch. Since this is the first study performing MethylCap-seq on zebra finch samples, prior to the genome-wide 
DNA methylation analysis, it was necessary to evaluate the effectiveness of this technique in zebra finch. 
Therefore, as a quality control, the untreated ZFTMA sample was also analyzed with RRBS, demonstrating that 
Gene Forward primer Reverse primer (biotinylated) Sequencing primer
BDNF GTAGAGTTGAGTTGGATAGATGT 1ACAATAATTCTACTACTATCCCTTCAA TGGATAGATGTTTGTATTATATGA
NGB GAGTTAGAATTGATGGGATTAAATAAGG 1CCTTACAAAAATAACCAAAAATAACACTTC GGGTAGTTGGGAGATATA
HES1-4 GGTGGGGTTATAAGTTTTTTGAT 1CTCCAAAAACATACTACAATTTTCACA GATAAATTAGAGTGAGGAAAAGAT
GABRD GTAGAAAGTATTTTTGGGTAAAAGTGGTAT 1AAGTGGTATTATTTATTTTAGTTAT TATACACCCAACAACACAAATATATCAA
ANK1 TAGTTTATGGGTTAGAAGGATAGGT 1ATAAAATCAACACATATTTCCCCTACA TAGGTGGTGGAGGGT
MMP9 AAGTGAGGGTTTATTTTTGAGGTAGTAT 1CCCCTAATTTCTCACCATTACTTCCTT GGTGGGATTTATTTTAGAGT
IKBKE GGGTGAGGGTGTTTGGTATAGT 1CCAACCCCTTCTCTTCCTATCA TGGGAGGGGGTGGTA
Legend: 1biotin-labeled
Table 2.  CpG pyrosequencing primer sequences.
ZFTMA & G266
cell lines
DMSO treatment AZA treatment
















Figure 1. Overview of experimental design. 
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higher RRBS CpG methylation degrees are clearly associated with more MethylCap-seq fragments (Fig. 3): for 
very low RRBS methylation percentages almost no fragments are picked up (Fig. 3a,b), whereas for very high 
methylation percentages, on average a high coverage is obtained (Fig. 3a). Note that Fig. 3b also illustrates that 
even for ~100% methylated loci, no fragments may be picked up by MethylCap-seq, most likely due to sev-
eral known biases inherent to the methodology46. Taken altogether, these results indicate that MethylCap-seq 
is an appropriate methodology for genome-wide mapping of DNA methylation in zebra finch, though only 
semi-quantitatively.




uniquely mapped reads Mapping percentage
MethylCap-seq
G266 DMSO 34,794,421 19,678,423 12,273,057 56.56%
G266 AZA 36,064,631 15,632,019 5,263,239 43.34%
ZFTMA DMSO 29,975,474 13,788,246 9,407,497 46.00%
ZFTMA AZA 33,496,076 17,508,214 4,741,451 52.25%
ZFTMA Untreated 35,015,944 15,617,024 11,173,357 44.60%
RRBS ZFTMA Untreated 73,660,217 20,939,730 NA 28.43%
b Cell line Treatment Input reads Total mapped reads Mapping percentage
RNA-seq
G266 DMSO 59,068,389 43,896,990 74.31%
G266 AZA 60,093,607 45,342,201 75.45%
ZFTMA DMSO 94,390,205 66,146,096 70.07%
ZFTMA AZA 63,714,282 45,870,652 71.99%
Table 3.  Summary of mapping statistics. (a) MethylCap-seq and RRBS. (b) RNA-seq.
Figure 2. Histogram of %CpG methylation. CpG methylation degrees obtained with RRBS of untreated 
ZFTMA cell line (CpG sites with a RRBS coverage ≥ 10).















































Figure 3. Comparison of MethylCap-seq and RRBS for the RRBS-covered CpGs (coverage ≥10). (a) Plot 
of the obtained RRBS CpG methylation degree and the average MethylCap-seq coverage. (b) Boxplots of the 
observed MethylCap-seq fragments for RRBS-covered CpGs with a CpG methylation degree starting from ≤ 1% 
to ≥ 99%, respectively.
www.nature.com/scientificreports/
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(Differential) methylation and expression analysis. By combining the MethylCap-seq data with 
the RRBS data, we identified 719,917 possibly methylated genomic regions, i.e. ‘Methylation Peaks’, of which 
60.29%, 31.32%, 5.39% and 3% are distributed in intergenic, intronic, exonic and promoter regions, respectively 
(see Supplementary Figure S1(a)). This peak distribution is not at all surprising, given the overall higher share of 
intronic/intergenic regions compared to exonic/promoter regions in the genome.
Examination of the methylation level per chromosome revealed overall similar methylation degrees between 
chromosomes (Supplementary Table S6). Furthermore, the distribution of methylation between exons, introns, 
promoters and intergenic regions showed only slight differences between chromosomes (Supplementary Figure S2). 
Additionally, it was examined if the intergenic methylation pattern distinguishes gene-deserts (gene-poor 
regions > 500 kb) from other intergenic regions. Indeed, after determining the methylation level of each group 
per chromosome, a t-test showed that gene-deserts are clearly less methylated than other intergenic regions 
(p-value = 0.0079 for the 21 chromosomes characterized by gene-deserts) (data not shown).
In a next step, a quantitative comparison was made between the DMSO- (= control) and AZA-treated 
(= demethylation treatment) samples making use of the R-package EdgeR32. Normalization was based on the 
reads that mapped between Methylation Peaks. Using an FDR of 10% (corresponding with a p-value of 0.0043), 
30,700 Methylation Peaks (= 4.26%) showed significantly less methylation after AZA-treatment. 1,996 of the 
18,318 annotated zebra finch genes (= 10.90%) had at least one of these 30,700 Methylation Peaks in their pro-
moter region (2000 bp up- and 500 bp downstream of transcription start site) (Supplementary Table S1).
To assess the impact of (variable) methylation on gene expression and to identify genes that are under DNA 
methylation control, RNA-seq experiments were performed. Of the mapped RNA-seq reads, only approximately 
50% were located in genomic regions that are annotated by Ensembl as coding regions, i.e. exons, likely reflect-
ing a still incomplete annotation of the zebra finch genome. For each sample, on average 70% of the known 
18,318 genes were covered with at least 10 reads in their coding region. Next, data normalization was performed 
with PoissonSeq33 as this method performed better upon visual inspection – profile of the scaling factor line 
through the scatterplot of the data points – compared to other normalization methods (e.g. TMM34, quantile and 
library size normalization) (data not shown). After normalization and EdgeR analysis (FDR = 0.1, correspond-
ing p-value = 0.0205), we identified 147 and 3,679 genes that were significantly down- and upregulated after 
AZA-treatment, respectively (Supplementary Tables S3 and S4).
Next, RNA- and MethylCap-seq results were compared. 357 of the 3,679 upregulated genes (= 10.35%) were 
featured by at least one Methylation Peak exhibiting significant AZA-dependent demethylation in the promoter 
region, and are thus under putative DNA methylation control (Supplementary Table S2). As an example, the data 
tracks of a couple of these genes are depicted for both cell lines in two circular plots31. Figure 4 shows the methyl-
ation profile (= MethylCap-seq tracks) of the promoter regions of 4 genes that are putatively epigenetically regu-
lated (i.e. HES1-4, heparin-binding EGF-like growth factor (HBEGF), ANK1 and IKBKE), while Fig. 5 also shows 
the corresponding expression profile (= RNA-seq tracks) for these genes. As songbirds are an ideal model to study 
memory formation, brain development and neuroplasticity, two of the depicted genes are neurobiologically rele-
vant (HES1-4 and ANK1), but in order to provide a general overview also two other genes (HBEGF and IKBKE) 
are added to the circular plots. These figures clearly show that these genes are characterized by AZA-induced 
demethylation of the promoter as well as re-expression.
In addition, also the MethylCap- and RNA-seq tracks of BDNF are shown. As stated earlier, it has been 
shown that BDNF is involved in synaptic plasticity with an expression inversely correlated with promoter DNA 
methylation. In our analysis, although BDNF expression was significantly upregulated after AZA-treatment 
(p-value = 5.31E-11, Fig. 5), we found no significantly demethylated Methylation Peaks in the BDNF promoter. 
However, visual inspection of the methylation profiles of the promoter region (Fig. 4) suggests considerable 
AZA-induced demethylation. Indeed, one particular Methylation Peak (highlighted in yellow in Fig. 4) received 
a p-value of 0.01 and despite the fact that this was just above the FDR threshold (corresponding with a p-value of 
0.0043), this still suggests methylation-dependent gene expression.
Enrichment analysis. As we aimed at the identification of epigenetically regulated genes, we were particu-
larly interested in DNA demethylation leading to upregulated gene expression. Therefore, we determined the 
global distribution of the functional genic locations (i.e. promoter, exon and intron) of those AZA-demethylated 
Methylation Peaks that are located in genes upregulated after AZA-treatment (Fig. 6(a)). Not unexpectedly – 
given the higher share of intronic regions compared to exonic/promoter regions in the genome – the major-
ity of these Methylation Peaks are located in intronic regions (68.27%). Additionally, a considerable number 
was found in the exonic (21.37%) and promoter regions (10.36%). In order to investigate whether one of these 
genic locations was relatively under- or overrepresented compared to random data, i.e. significantly decreased or 
enriched, we performed an enrichment analysis. By comparing the genomic distributions of 1,000 random sam-
ples (Fig. 6(b)) with the distribution shown in Fig. 6(a), a significant overrepresentation of AZA-demethylated 
loci was found for promoter and exonic regions whereas a significant underrepresentation was found for intronic 
regions (p-values < 0.001). No significant enrichment was found for a particular exon number (data not shown).
When looking only at the genome-wide methylation data, i.e. including intergenic regions and not taking into 
account the RNA-seq expression data, similar results were obtained: compared to random data, AZA-induced 
demethylation was relatively enriched in exonic and promoter regions, but decreased in intronic and intergenic 
regions (p-values < 0.001, see Supplementary Figure S1(b)).
Ingenuity Pathway Analysis. Table 4 shows the top overrepresented disease and function categories 
resulting from an IPA of the 357 putatively epigenetically regulated genes (i.e. upregulated expression and 
down-methylated promoter after AZA-treatment). As can be noted from Table 4, neurological disease is clas-
sified as the top overrepresented disease category (Benjamini-Hochberg adjusted p-values between 6.1E-5 and 
www.nature.com/scientificreports/
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6.41E-2). Next to neurological diseases, this gene cluster also shows significant association with cancer and psy-
chological disorders. A list of genes that contribute to each of the significant categories as well as a list of genes that 
contribute to each of the specific diseases or functions in each of the categories can be found in Supplementary 
Table S7 and Table S8, respectively.
Validation: Zebra finch Exon Arrays, qPCR and single locus specific DNA methylation quantifi-
cation by CpG pyrosequencing. In order to confirm the RNA-seq findings using a larger number of bio-
logical replicates, we performed zebra finch Exon Arrays (Affymetrix, custom designed). In addition, the inverse 
correlation between DNA methylation and expression levels was validated using pyrosequencing and qPCR for a 
subset of genes. 14 AZA-treated RNA samples, corresponding to 7 ZFTMA and 7 G266 samples, were compared 
to 11 controls (DMSO-treated), 5 from ZFTMA and 6 from G266 using Exon Arrays. With this platform, it is pos-
sible to detect expression of 17,882 Ensembl-NCBI annotated genes. 3,826 genes were found to be differentially 
expressed in the RNA-seq experiment, out of which 3,533 are present on the array. Hence, the validation covered 
92.3% of the RNA-seq differentially expressed genes. Genes were considered differentially expressed when the 
p-value was lower than or equal to 0.05. This way, differential expression could be confirmed for 2,398 out of 3,826 
(62.7%) genes: 109 out of 147 (74.1%) down-regulated genes and 2,289 out of 3,679 (62.2%) up-regulated genes.
In order to determine whether the expression level correlates to the methylation status, 7 genes were selected 
that showed a significant increase in gene expression and decrease in promoter DNA methylation in both 
RNA-seq and Exon Arrays and in MethylCap-seq experiments, respectively: BDNF, NGB, HES1-4, GABRD, 
ANK1, MMP9 and IKBKE. To validate our findings three independent biological samples were treated with either 
DMSO or AZA and for these 7 genes (i) qPCR was carried out to validate the induction of mRNA expression 
and (ii) CpG pyrosequencing was performed to validate DNA methylation changes in the promoter region of the 
corresponding genes.
For each gene, qPCR results were consistent with the obtained RNA-seq results, i.e. the mRNA expression of 
these genes is significantly upregulated by AZA-treatment in both cell lines (Fig. 7 and Table 5). Also, for 6 genes, 
Figure 4. Circular representation of the normalized methylation profiles of 5 genes (BDNF, ANK1, 
HBEGF, HES4 and IKBKE). Promoter regions of the 5 depicted genes with the corresponding methylation 
profiles for both DMSO- and AZA-treatments. From inner to outer circle: (i, ii) MethylCap-seq data of DMSO-
treated ZFTMA and G266 cell lines, respectively. (iii, iv) MethylCap-seq data of AZA-treated ZFTMA and G266 
cell lines, respectively. (v) Gene promoter annotation. Significantly down-methylated Methylation Peaks are 
highlighted in grey. Apart from BDNF, all genes are part of the 357 genes found to be putatively regulated by 
promoter methylation (i.e. AZA-induced down-methylated promoter methylation and upregulated expression), 
while for BDNF only expression was significantly upregulated. For BDNF, the defined Methylation Peak in the 
promoter region for which methylation was clearly reduced – yet not significant at FDR 0.1 – is highlighted 
in yellow. From this figure it is clear that these genes are characterized by AZA-induced demethylation of the 
promoter region.
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1 0Scientific RepoRts | 6:20957 | DOI: 10.1038/srep20957
the change in DNA methylation levels in the promoter was confirmed by pyrosequencing, even for differential 
methylated BDNF peaks which revealed borderline statistical significance in the MethylCap-seq results (Fig. 8, 
Figure S3 and Table 5). Note that for MMP9 the change in promoter methylation was only confirmed in one cell 
line (ZFTMA). Although IKBKE was found to be differentially expressed between both treatments – both with 
Figure 5. Circular representation of the normalized expression profiles of 5 genes (BDNF, ANK1, 
HBEGF, HES4 and IKBKE). Genic regions with the corresponding expression profiles for both DMSO- and 
AZA-treatments. From inner to outer circle: (i, ii) RNA-seq data of DMSO-treated ZFTMA and G266 cell 
lines, respectively. (iii, iv) RNA-seq data of AZA-treated ZFTMA and G266 cell lines, respectively. (v) Genic 
annotation (Ensembl). Due to the large extent of some genes, instead of the whole genic range, a subregion of 
HBEGF, ANK1 and IKBKE is shown. In both figures, the two G266 tracks are equally scaled, as well as both 
ZFTMA tracks. Apart from BDNF, all genes are part of the 357 genes found to be putatively regulated by 
promoter methylation (i.e. AZA-induced down-methylated promoter methylation and upregulated expression), 
while for BDNF only the expression was significantly upregulated. From this figure it is clear that these genes are 







Figure 6. Genic distribution of the Methylation Peaks located in the upregulated genes after AZA-
treatment. (a) Distribution of the Methylation Peaks featured by significant AZA-induced demethylation.  
(b) Mean genic classification of random Methylation Peaks resulting from 1,000 iterations.
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RNA-seq and qPCR – the methylation differences found with MethylCap-seq could not be validated with CpG 
pyrosequencing (see Discussion).
Discussion
The methylomes of two zebra finch cell lines were profiled by MethylCap-seq. Both G266 (male, diploid) and 
ZFTMA (female, tetraploid) cell lines were obtained from spontaneous, non-neuronal tumors and provide an 
efficient alternative for whole-animal manipulations. As this study is the first to use MethylCap-seq to provide a 
genome-wide DNA methylation profile of DNA originating from zebra finch samples, we first evaluated the effec-
tiveness of this technique on an untreated ZFTMA cell line. By comparing the MethylCap-seq data with RRBS 
CpG methylation degrees, MethylCap-seq indeed proved to be an appropriate methodology for genome-wide 
mapping of DNA methylation in zebra finches. The fact that CpG pyrosequencing validated promoter meth-
ylation changes in 6 out of the 7 selected genes further supports our conclusion regarding MethylCap-seq as a 
suitable methodology in zebra finches, though it only provides a semi-quantitative indication of the degree of 
methylation.
Based on MethylCap-seq data of AZA-treated samples and controls (solvent, DMSO), an in-house peak call-
ing method identified 719,917 Methylation Peaks of which 30,700 showed significantly less methylation after 
AZA-treatment. Not unexpectedly, these down-methylated Methylation Peaks were significantly enriched for 
exonic and promoter regions. Complemented with additional RNA-seq data, we subsequently identified 357 genes 
featured by expression under putative DNA methylation control, including ANK1 (Supplementary Table S2). 
Interestingly, two independent studies recently demonstrated hypermethylation of ANK1 in the brain of 
Alzheimer’s patients41,47. ANK1 produces ankyrin 1, an essential structural component of the cell outer mem-
branes. Furthermore, this epigenetic alteration appears to occur early on in the disease, making them potential 
biomarkers. Our results further confirm that ANK1 expression is regulated by promoter DNA methylation, at 
least in zebra finch.
Subsequent IPA pathway analysis of the obtained list of genes regulated by DNA methylation showed obvious 
enrichment for neurological pathways/networks and associations with neurological diseases. Besides neurologi-
cal diseases and organismal survival, cancer is also in the top three of overrepresented diseases and function cat-
egories. This is not surprising, as (i) we are working with cell lines derived from tumor material and (ii) AZA has 
been shown to have anti-cancer effects by reactivating tumor suppressor genes that are silenced by aberrant DNA 
methylation48. Due to these anti-cancer properties, it has already been used in some clinical trials for leukemia, 
myelodysplastic syndrome and non-small cell lung carcinoma49.
Exon Array validation of RNA-seq results could confirm differential expression for 62.7% of genes, indicating 
a high level of agreement between RNA-seq and Exon Array results. The possibility of 100% cross-platform agree-
ment is precluded by differences specific to each platform. In contrast to RNA-seq, microarrays have for example 
the inherent limitation that they can only detect a limited number of genes (in this case 92% of the target genes are 
detectable by the array) and have a limited dynamic detection range owing to both background and saturation of 
signals50. Moreover, the statistical power and the number of replicates used was different for both platforms, what 
can further explain the differences in results between platforms.
For a subset of genes putatively regulated by DNA methylation, expression and methylation changes following 
AZA-treatment were validated using respectively qPCR and CpG pyrosequencing on bisulfite-treated samples. 
For 6 of the 7 selected genes – BDNF, NGB, HES1-4, GABRD, ANK1 and MMP9 – we could validate both pro-
moter methylation and gene expression changes caused by AZA-mediated demethylation. However, whereas the 
Category p-value - FDR
Neurological Disease 6,1E-05-6,41E-02
Cancer 3,89E-03-6,41E-02





Skeletal and Muscular Disorders 1,03E-02-6,41E-02
Cell Cycle 1,03E-02-6,41E-02
Amino Acid Metabolism 1,03E-02-6,41E-02
Molecular Transport 1,03E-02-6,41E-02
Small Molecule Biochemistry 1,03E-02-6,41E-02
Gastrointestinal Disease 1,16E-02-6,41E-02
Cardiovascular System Development and 
Function 1,16E-02-6,41E-02
Organismal Development 1,16E-02-6,41E-02
Table 4.  Top overrepresented disease and function categories as determined by IPA pathway analysis. 
Categories, corresponding p-values and false discovery rates are shown for the analysis done on the list of 357 
AZA-induced upregulated zebra finch genes with at least one significantly down-methylated Methylation Peak 
in their promoter region.
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Figure 7. qPCR validation of RNA-seq results. For validation 7 genes were selected that showed a significant 
increase in gene expression and decrease in promoter DNA methylation in RNA-seq, Exon Arrays and MethylCap-
seq experiments, respectively. This figure shows the impact of AZA (1 μ M) treatment on BDNF, NGB, HES1/4, 
GABRD, ANK1, MMP9 and IKBKE gene expression in ZFTMA and G266 cell lines, relative to a DMSO solvent 
control. Results were normalized to the geometric mean of reference genes RPS13, RPL30 and GAPDH. The bar 
graphs represent relative mRNA expression (mean ± SEM) of three independent experiments. In all cases, the 
changes in mRNA expression after AZA treatment could be validated by qPCR (2-way-ANOVA).
www.nature.com/scientificreports/
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demethylation effect of AZA is very clear in MethylCap-seq data, only modest effects (change of 1–19%) could be 
observed by pyrosequencing (Supplementary Figure S3). Of special note, though pyrosequencing results demon-
strated only moderate methylation changes, subsequent analysis still showed a significant distinction between the 
DMSO- and AZA-treated samples (Table 5). One possible explanation for this observation is that accumulation of 
small individual methylation changes in multiple subsequent CpG sequences may culminate in drastic changes in 
affinity of MethylCap-seq. In contrast, CpG pyrosequencing relies on nucleotide-based sequencing of individual 
CpG motifs in a stretch of less than 100 bp within a Methylation Peak, so there is always the possibility that there 
are bigger CpG methylation changes up/downstream of the pyrosequencing amplicon – which could explain why 
the pyrosequencing results of IKBKE were not significant. Alternatively, secondary DNA damage in AZA-treated 
samples may further reduce the affinity for MBD and overestimate the absolute decrease in DNA methylation 
levels51,52. Besides, mixed changes in DNA methylation and hydroxymethylation by AZA-treatment can differ-
entially affect MBD2 binding affinity, whereas bisulfite CpG pyrosequencing can not discriminate between both 
epigenetic modifications53,54.
Nevertheless, the magnitude of DNA methylation changes following AZA-treatment is similar to effects 
reported in gene promoter-specific pyrosequencing assays performed in cancer (patient) samples (human, 
mouse)55.
As already noted in the introduction, songbirds – and zebra finches in particular – are intensively studied by 
neuroscientists. Dynamic CpG (de)methylation and subsequent gene expression changes play an important role 
in neuronal functions like learning and memory formation, highlighting the relevance of this study. There are 




ZFTMA G266 ZFTMA G266
BDNF 1.09E-11 6.22E-11 2.03E-4 2.55E-4
NGB 3.25E-6 2.12E-8 6.74E-3 3.53E-2
HES1-4 3.25E-6 2.12E-8 6.97E-3 8.85E-3
GABRD 1.41E-11 3.82E-2 1.09E-3 2.60E-2
ANK1 2.03E-5 1.12E-7 6.40E-8 5.03E-08
MMP9 7.96E-13 1.71E-14 3.81E-02 2.80E-01
IKBKE 1.34E-09 8.06E-08 3.41E-01 5.69E-01
Table 5.  Results of qPCR and CpG pyrosequencing validation. 7 genes were selected that showed a 
significant increase in gene expression (both in RNA-seq and Exon Arrays) and decrease in promoter DNA 
methylation (MethylCap-seq). qPCR and CpG-pyrosequencing validation experiments were performed 
comparing expression and methylation values between DMSO- and AZA-treated samples. The obtained gene-
specific p-values per cell line clearly show a significant difference in expression for each of the genes for the two 
treatments. Methylation differences between treatments could be validated by CpG pyrosequencing in all genes 
except for IKBKE. For MMP9 the change in promoter methylation was only confirmed in the ZFTMA cell line.
Figure 8. CpG pyrosequencing validation of MethylCap-seq results. For validation 7 genes were selected 
that showed a significant increase in gene expression and decrease in promoter DNA methylation in RNA-seq, 
Exon Arrays and MethylCap-seq experiments, respectively. This figure depicts changes in DNA methylation 
of specific CpG sites in the promoters of BDNF, NGB, HES1/4, GABRD, ANK1, MMP9 and IKBKE after 
AZA (1 μ M) treatment in ZFTMA and G266 cell lines, relative to DMSO solvent control. The shown DNA 
methylation levels represent the mean of three independent experiments. Only CpG sites that passed 
quality control were considered. The NGB gene was found to contain a SNP in the G266 cell line at position 
chr5:39,429,316, which was corrected for in the analysis. Methylation changes could be validated for each of the 
genes, except for IKBKE (2-way ANOVA). For MMP9 the change in promoter methylation was only confirmed 
in the ZFTMA cell line.
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(i)   A first note worth considering is that used cell lines do not originate from brain tissue but from spontaneous, 
non-neuronal, tumors. However, by comparing the expression profile of these cell lines with the expres-
sion profile of the zebra finch auditory lobule, Balakrishnan et al.11 demonstrated that many neurobiologi-
cally relevant genes are expressed in both G266 and ZFTMA cell lines. Moreover, additional overlap with 
microarray data of Drnevich et al. (Songbird Neurogenomics (SoNG) Initiative (SoNG 20 K microarray), 
488 songbird brain samples56), showed that 104 of the found 357 epigenetically regulated genes were signifi-
cantly differentially expressed (p < 2.6E-06) in the zebra finch microarray contrasts. This number increased 
to 134 out of 357 when a less stringent p-value of 0.001 was used to call a gene differentially expressed in 
the microarray data. A list of these genes is added in the Supplementary Tables (S5). Finally, the fact that 
‘neurological diseases’ is the most overrepresented disease category in the pathway analysis together with 
the plethora of genes associated with brain function in our epigenetic analysis further illustrates the utility 
of these cell lines to study neurobiologically relevant genes.
(ii)   A subset of tissue-related genes may need tissue-specific transcription factors to be expressed. When these 
transcription factors are not present in the cell lines, these genes will not be expressed, even if the promoter 
is demethylated. As a result, our list of 357 genes under putative DNA methylation control could be incom-
plete for the brain. Therefore, a list of genes with changes in promoter methylation, independent of a change 
in expression, is also included as Supplementary Table S1.
(iii)   Finally, as G266 and ZFTMA are immortalized cell lines, it is possible that some of the found epigenetically 
regulated genes are involved in tumorgenesis, particularly when taking into account that (i) DNA meth-
ylation deregulation is common in cancer57 and (ii) AZA-treatment has been shown to reactivate tumor 
suppressor genes48.
(iv)   The zebra finch reference genome and its annotation are currently still incomplete. This is partially reflected 
in the rather “low” unique mapping efficiency of the RRBS library. Indeed, besides sequencing quality, also 
the quality of the reference genome (particularly completeness) and intrinsic features of the studied species 
(e.g. overall degree of methylation) are anticipated to have a profound impact on mapping percentages. In 
high quality human RRBS data for example, mapping percentages are approaching 80%58. One possibility 
to increase RRBS mapping efficiencies in this study was to lower the mapping stringency, but as RRBS was 
particularly used to validate the MethylCap-seq approach rather than to give biological insight as such, this 
option was not further explored.
We believe that this study can be an important starting point for future epigenetic studies in zebra finch. The 
genome-wide map of the zebra finch methylome, for both control and AZA-treated samples, allows the identi-
fication of sites that are practically always methylated, or for which the methylation status is highly variable in 
different settings. Furthermore, we provide a list of genes that are putatively regulated by DNA methylation in the 
promoter region. The next step will be to investigate whether DNA methylation also regulates the expression of 
these genes in vivo and under which circumstances. DNA methylation changes are e.g. known to play an impor-
tant role during learning processes59, brain development16 and ageing60, and are known to occur in response 
to (sex) hormone exposure61 or environmental cues62. Since epigenetic regulation is emerging as an important 
mechanism in sexual differentiation63,64 in our future work we will focus on the underlying epigenetic mecha-
nisms of sexual dimorphic brain development during vocal learning in the zebra finch.
In conclusion, using two zebra finch cell lines, we were able to validate the MethylCap-seq methodology 
in zebra finch samples. To the best of our knowledge, this study provides the first genome-wide DNA meth-
ylation map of the zebra finch genome as well as a comprehensive set of genes of which transcription is under 
putative DNA methylation control. Interestingly, this subset included many neurobiologically relevant genes, 
further enlightened by the pathway analysis showing obvious enrichment for neurological pathways/networks 
and associations with neurological diseases. As such, this zebra finch draft methylome may become an attractive 
data-mining tool for (neuro)epigenetic studies in songbirds.
Data Submission
The data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus and are accessi-
ble through GEO Series accession numbers GSE61060 and GSE71344 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc= GSE61060, http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc= GSE71344).
Next to these files, RRBS data has also been made available in BAM-format, which can be downloaded from 
the author’s website: http://www.biobix.be/data-2/zebrafinch/.
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